Cycloheximide

Cycloheximide

别名: NSC-185, Actidione, Naramycin A, CHX, FT 3422-2, NM-MCD 80

中文名称：放线菌酮，环己酰亚胺

此产品请避光密封保存。

目录号：S7418

Purity: 99%

Cycloheximide (NSC-185, Actidione, Naramycin A, CHX, FT 3422-2, NM-MCD 80)，一种抗真菌抗生素，是一种真核生物蛋白质合成（protein synthesis）抑制剂，对体内蛋白质合（protein synthesis）和 RNA 合成（RNA synthesis）的 IC50 分别为 532.5 nM 和 2880 nM。Cycloheximide抑制铁死亡并抑制自噬。Cycloheximide (NSC-185) 可用于诱导记忆障碍动物模型。在溶液中不稳定，请现配现用！此产品为危化品（急性毒性/易燃/皮肤腐蚀），请在穿戴防护面罩、防护手套和防护服后使用。

已取得危险化学品经营许可

Cycloheximide Chemical Structure

CAS: 66-81-9

规格

价格

库存

购买数量

200mg

647.01

现货

0

1

2

3

4

5

6

7

8

9

10

500mg

794.43

现货

0

1

2

3

4

5

6

7

8

9

10

更大包装

有超大折扣

点击询价

400-668-6834

info@selleck.cn

加入购物车

产品质控

批次：

S741805

S741804

纯度：

99%

Nature medicine文章证明Selleck质量第一

COA

SDS

说明书

Nature medicine文章证明Selleck质量第一

COA

SDS

说明书

99

Cycloheximide相关产品

相关产品

Tolnaftate

Amorolfine HCl

Neticonazole

Pseudolaric Acid B

Climbazole

Bifonazole

Butylparaben

Isavuconazole

Thimerosal

Neticonazole Hydrochloride

Juglone

点击展开

相关化合物库

激酶抑制剂库

FDA药物库

天然产物库

已知活性药物库-I

高选择性抑制剂库

点击展开

×

Fungal信号通路图

细胞实验数据示例

细胞系

实验类型

给药浓度

孵育时间

活性描述

文献信息(PMID)

MCF7

Function assay

10 ug/mL

1 hr

Inhibition of HIF1alpha RNA translation in human MCF7 cells at 10 ug/mL pretreated for 1 hr prior to metabolic labeling by SDS-PAGE analysis

22607231

AGS

Apoptosis assay

150 ug/mL

48 hrs

Induction of apoptosis in human AGS cells assessed as early apoptosis level at 150 ug/mL after 48 hrs by Annexin V-FITC apoptosis assay

21899268

T47D

Function assay

10 uM

4 hrs

Inhibition of 1,10-phenanthroline-induced HIF1alpha activation in human T47D cells at 10 uM after 4 hrs by Western blotting

15974627

T47D

Function assay

0.3 uM

4 hrs

Inhibition of 1,10-phenanthroline-induced HIF1alpha activation in human T47D cells at 0.3 uM after 4 hrs by Western blotting

15974627

T47D

Function assay

3 uM

16 hrs

Inhibition of hypoxia-induced HIF1 activation in human T47D cells at 3 uM after 16 hrs by luciferase reporter gene assay

15974627

T47D

Function assay

0.7 uM

16 hrs

Inhibition of 1,10-phenanthroline-induced HIF1 activation in human T47D cells at 0.7 uM after 16 hrs by luciferase reporter gene assay

15974627

T47D

Function assay

10 uM

16 hrs

Inhibition of hypoxia-induced VEGF expression in human T47D cells at 10 uM after 16 hrs by ELISA

15974627

T47D

Function assay

0.3 uM

4 hrs

Inhibition of hypoxia-induced HIF1alpha activation in human T47D cells at 0.3 uM after 4 hrs by Western blotting

15974627

T47D

Function assay

10 uM

4 hrs

Inhibition of hypoxia-induced HIF1alpha activation in human T47D cells at 10 uM after 4 hrs by Western blotting

15974627

HEK293T

Function assay

50 uM

30 mins

Effect on polyribosome profiling in human HEK293T cells assessed as depletion of polysomes at 50 uM after 30 mins by spectrophotometry

20118940

T47D

Antiproliferative assay

10 uM

48 hrs

Antiproliferative activity against human T47D cells at 10 uM after 48 hrs by SRB assay

23434131

MDA-MB-231

Antiproliferative assay

10 uM

48 hrs

Antiproliferative activity against human MDA-MB-231 cells at 10 uM after 48 hrs by SRB assay

23434131

NCI-H460

Function assay

10 ug/mL

up to 9 hrs

Reduction of HSP1 stability in human NCI-H460 cells assessed as protein degradation at 10 ug/mL up to 9 hrs by Western blot analysis

24746225

HeLa

Cytotoxicity assay

25 uM

18 hrs

Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 25 uM after 18 hrs by inverse MTT assay

25028062

RAW264.7

Function assay

70 uM

6 hrs

Inhibition of luminescence emission in mouse RAW264.7 cells transfected with luciferase plasmid containing universal promoter PKG at 70 uM after 6 hrs by luciferase reporter gene assay

25667960

HepG2-A16-CD81

Function assay

10 uM

NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration, IC50 = 0.0781 μM.

22096101

neural precursor cells

Function assay

3 uM

Induction of neurosphere phenotype changes in mouse neural precursor cells at 3 uM

17417631

Jurkat T-cells

Function assay

48 hours

Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours, IC50 = 0.93 μM.

11052798

Jurkat T-cells

Function assay

48 hours

Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours, IC80 = 1.54 μM.

11052798

HeLa

Cytotoxicity assay

24 hrs

Cytotoxicity against human HeLa cells after 24 hrs, CD50 = 0.1 μM.

18394884

3T3

Cytotoxicity assay

72 hrs

Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.912 μM.

18771242

HeLa

Function assay

2 hrs

Inhibition of protein synthesis in human HeLa cells assessed as [35S]cysteine/methionine utilization after 2 hrs by scintillation spectroscopy, IC50 = 0.5325 μM.

20118940

HeLa

Function assay

2 hrs

Inhibition of transcriptional activity in human HeLa cells assessed as [3H]uridine utilization after 2 hrs by scintillation counting, IC50 = 2.8801 μM.

20118940

3T3

Cytotoxicity assay

72 hrs

Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.26 μM.

20356064

BESM

Function assay

88 hrs

Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay, EC50 = 0.4 μM.

20547819

NIH/3T3

Cytotoxicity assay

48 hrs

Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay, IC50 = 1.1 μM.

21899268

MDA-MB-231

Cytotoxicity assay

48 hrs

Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 1.2 μM.

21899268

AGS

Cytotoxicity assay

48 hrs

Cytotoxicity against human AGS cells after 48 hrs by MTT assay, IC50 = 3.6 μM.

21899268

HT-29

Cytotoxicity assay

48 hrs

Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay, IC50 = 12.8 μM.

21899268

3T3

Cytotoxicity assay

72 hrs

Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.26 μM.

22437110

PA1

Cytotoxicity assay

24 hrs

Cytotoxicity against human PA1 cells after 24 hrs by MTT assay, IC50 = 40.6 μM.

23202484

PA1

Growth inhibition assay

24 hrs

Growth inhibition of human PA1 cells after 24 hrs by MTT assay, IC50 = 40.6 μM.

28011220

CEM

Cytotoxicity assay

5 days

Cytotoxicity against human CEM cells assessed as decrease in cell viability after 5 days by MTT assay, IC50 = 0.2 μM.

29778528

Vero

Cytotoxicity assay

3 days

Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 3 days by MTT assay, IC50 = 0.2 μM.

29778528

3T3

Cytotoxicity assay

48 hrs

Cytotoxicity against rat 3T3 cells after 48 hrs by MTT assay, IC50 = 0.61 μM.

30146096

CEM

Anticancer assay

Tested in vitro for anticancer activity against CEM cells, IC50 = 0.12 μM.

10072683

9L

Anticancer assay

Tested in vitro for anticancer activity against 9L cells, IC50 = 0.2 μM.

10072683

SK-MEL-28

Anticancer assay

Tested in vitro for anticancer activity against SK-MEL-28 cells, IC50 = 1 μM.

10072683

Vero

Cytotoxicity assay

Tested in vitro for cytotoxicity against Vero cells, IC50 = 1.2 μM.

10072683

LNCaP

Anticancer assay

Tested in vitro for anticancer activity against LNCaP cells, IC50 = 1.2 μM.

10072683

MCF-7

Anticancer assay

Tested in vitro for anticancer activity against MCF-7 cells, IC50 = 1.5 μM.

10072683

PBM

Cytotoxicity assay

Tested in vitro for cytotoxicity against PBM cells, IC50 = 2.1 μM.

10072683

HepG2

Anticancer assay

Tested in vitro for anticancer activity against HepG2 cells, IC50 = 2.5 μM.

10072683

SK-MES-1

Anticancer assay

Tested in vitro for anticancer activity against SK-MES-1 cells, IC50 = 2.7 μM.

10072683

PC-3

Anticancer assay

Tested in vitro for anticancer activity against PC-3 cells, IC50 = 3.5 μM.

10072683

Jurkat T-cells

Function assay

Inhibitory concentration against Human Jurkat T cells, IC50 = 0.93 μM.

10212121

Jurkat T-cells

Function assay

Inhibitory concentration against Human Jurkat T cells, IC80 = 1.54 μM.

10212121

CEM

Cytotoxicity assay

Cytotoxicity was determined in CEM cells, relative to RVT, IC50 = 0.08 μM.

15081000

PBM

Cytotoxicity assay

Cytotoxicity was determined in PBM cells, relative to RVT, IC50 = 0.46 μM.

15081000

Vero

Cytotoxicity assay

Cytotoxicity was determined in Vero cells, relative to RVT, IC50 = 0.53 μM.

15081000

HeLa

Function assay

Inhibition of hypoxia-induced HIF1 activation in human HeLa cells by luciferase reporter gene assay, IC50 = 0.036 μM.

15974627

medulloblastoma cells

Antiproliferative assay

Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay, EC50 = 0.042 μM.

17417631

neural precursor cells

Antiproliferative assay

Antiproliferative activity against mouse neural precursor cells by colony formation assay, EC50 = 0.054 μM.

17417631

astrocyte cells

Antiproliferative assay

Antiproliferative activity against mouse astrocyte cells by MTT assay, EC50 = 0.071 μM.

17417631

neural precursor cells

Antiproliferative assay

Antiproliferative activity against mouse neural precursor cells by MTT assay, EC50 = 0.142 μM.

17417631

HepG2

Function assay

HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells, IC50 = 0.047 μM.

22586124

3T3

Cytotoxicity assay

Cytotoxicity against mouse 3T3 cells by SRB assay, IC50 = 0.3 μM.

29247859

TC32

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells

29435139

A673

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells

29435139

DAOY

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells

29435139

Saos-2

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells

29435139

BT-37

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells

29435139

RD

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells

29435139

SK-N-SH

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells

29435139

BT-12

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells

29435139

NB1643

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells

29435139

OHS-50

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells

29435139

BT-12

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells

29435139

LAN-5

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells

29435139

Rh41

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells

29435139

SK-N-SH

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells

29435139

A673

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)

29435139

BT-37

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells

29435139

Rh30

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells

29435139

U-2 OS

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells

29435139

OHS-50

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells

29435139

RD

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells

29435139

SJ-GBM2

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells

29435139

SK-N-MC

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells

29435139

NB-EBc1

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells

29435139

SK-N-MC

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells

29435139

SJ-GBM2

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells

29435139

TC32

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells

29435139

SJ-GBM2

qHTS assay

qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells

29435139

HeLa

Cytotoxicity assay

Cytotoxicity against human HeLa cells assessed as inhibition of DNA replication by imaging analysis

18066055

HeLa

Function assay

Inhibition of mitosis in human HeLa cells by imaging analysis

18066055

点击查看更多细胞系数据

生物活性

产品描述

Cycloheximide (NSC-185, Actidione, Naramycin A, CHX, FT 3422-2, NM-MCD 80)，一种抗真菌抗生素，是一种真核生物蛋白质合成（protein synthesis）抑制剂，对体内蛋白质合（protein synthesis）和 RNA 合成（RNA synthesis）的 IC50 分别为 532.5 nM 和 2880 nM。Cycloheximide抑制铁死亡并抑制自噬。Cycloheximide (NSC-185) 可用于诱导记忆障碍动物模型。在溶液中不稳定，请现配现用！此产品为危化品（急性毒性/易燃/皮肤腐蚀），请在穿戴防护面罩、防护手套和防护服后使用。

临床试验信息

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number

Recruitment

Conditions

Sponsor/Collaborators

Start Date

Phases

NCT03700788

Not yet recruiting

Apical Periodontitis

University of Southern California

May 30 2023

Phase 3

NCT05506566

Recruiting

Tumor|Positron-Emission Tomography

First Affiliated Hospital of Fujian Medical University

May 1 2022

Phase 1|Phase 2

NCT02202304

Withdrawn

Periodontal Disease|Caries

Rosa Moreno Lopez|Ivoclar Vivadent AG|University of Aberdeen

September 10 2017

Phase 4

NCT01521325

Completed

Mesothelioma|Pancreatic Cancer|Ovarian Cancer|Non-small Cell Lung Cancer

Morphotek

September 2011

Phase 1

NCT02168374

Completed

Dental Caries

Aline R F de Castilho|Fundação de Amparo à Pesquisa do Estado de São Paulo|University of Campinas Brazil

March 2008

Phase 2

参考文献

https://pubmed.ncbi.nlm.nih.gov/26548846/

https://pubmed.ncbi.nlm.nih.gov/22610049/

https://pubmed.ncbi.nlm.nih.gov/5541758/

https://pubmed.ncbi.nlm.nih.gov/30916348/

+ 展开

化学信息&溶解度

分子量

281.35

分子式

C15H23NO4

CAS号

66-81-9

SDF

--

Smiles

CC1CC(C(=O)C(C1)C(CC2CC(=O)NC(=O)C2)O)C

储存条件(自收到货起)

3年 -20°C(避光) 粉状

储备液保存和期限建议分装储备液，避免反复冻融！

1年-80°C溶于溶剂

1个月-20°C溶于溶剂

体外溶解度 批次：

S741805

S741804

DMSO

: 56 mg/mL

(

(199.04 mM)

；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Ethanol

: 56 mg/mL

(199.04 mM)

Water

: 15 mg/mL

(53.31 mM)

DMSO

: 56 mg/mL

(

(199.04 mM)

；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Ethanol

: 56 mg/mL

(199.04 mM)

Water

: 15 mg/mL

(53.31 mM)

摩尔浓度计算器

体内溶解配方批次：

S741805

S741804

现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂

动物体内配方计算器

均匀悬浊液

CMC-NA

≥5mg/ml

以 1 mL 工作液为例，取 5 mg该产品加到 1 ml CMC-NA 溶液中，混合均匀，即可得工作液浓度为 5 mg/ml的均匀悬浊液。

均匀悬浊液

CMC-NA

≥5mg/ml

以 1 mL 工作液为例，取 5 mg该产品加到 1 ml CMC-NA 溶液中，混合均匀，即可得工作液浓度为 5 mg/ml的均匀悬浊液。

实验计算

摩尔浓度计算器

质量

浓度

体积

分子量

pg

ng

μg

mg

g

kg

=

fM

pM

nM

μM

mM

M

×

nL

μL

mL

L

×

计算

重置

稀释计算器

分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

g

每只动物给药体积 μL

动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO +

%

PEG300

Corn oil

+

% Tween 80

+

% ddH2O

%DMSO+

%

Corn oil

PEG300

计算重置

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg

药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL

DMSO母液，加入μL PEG300，混匀澄清后加入μL

Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。

体内配方配制方法：取μL

DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；

2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

* 姓名

请输入您的姓名

* 邮箱

请输入您的邮箱地址

请输入一个有效的邮箱地址

电话

* 留言内容

请写点东西给我们